Around 2000, the development of both agents in the West was discontinued due to concerns about the formation of antidrug antibodies that cross-reacted with endogenous TPO, causing thrombocytopenia (Chen et al., 2023; Li et al., 2001; Soff et al., 2019). Here, TPO is linked to Thrombocytopenia.